Literature DB >> 12901866

Norepinephrine induces hepatic fibrogenesis in leptin deficient ob/ob mice.

Jude A Oben1, Tania Roskams, Shiqi Yang, Huizhi Lin, Nicoletta Sinelli, Zhiping Li, Michael Torbenson, Steven A Thomas, Anna Mae Diehl.   

Abstract

Leptin's actions on certain cells require a leptin-inducible neurotransmitter, norepinephrine (NE). NE modulates hepatic fibrosis. Therefore, decreased NE may explain why leptin deficiency inhibits hepatic fibrosis. We manipulated adrenergic activity in leptin-deficient ob/ob mice, leptin-sufficient, dopamine beta-hydroxylase deficient (Dbh(-/-)) mice, and HSC cultures to determine if leptin requires NE to activate HSC and induce hepatic fibrosis. ob/ob mice have chronic liver injury, but reduced numbers of HSC. Supplemental leptin increases HSC, suggesting that leptin-dependent, injury-related factors permit expansion of HSC populations. NE also increases HSC numbers and activation, normalizing fibrogenesis. When fed hepatotoxic diets, NE-deficient Dbh(-/-) mice fail to accumulate activated HSC and have impaired fibrogenesis unless treated with adrenergic agonists. NE acts directly on HSC to modulate leptin's actions because leptin increases HSC proliferation and prazosin, an alpha-adrenoceptor antagonist, inhibits this. Thus, leptin permits injury-related increases in adrenergic activity and requires NE to activate HSC and induce hepatic fibrogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12901866     DOI: 10.1016/s0006-291x(03)01360-3

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

1.  Genetic covariance between gamma-glutamyl transpeptidase and fatty liver risk factors: role of beta2-adrenergic receptor genetic variation in twins.

Authors:  Rohit Loomba; Fangwen Rao; Lian Zhang; Srikrishna Khandrika; Michael G Ziegler; David A Brenner; Daniel T O'Connor
Journal:  Gastroenterology       Date:  2010-06-09       Impact factor: 22.682

Review 2.  Cytokines and the pathogenesis of non-alcoholic steatohepatitis.

Authors:  A M Diehl; Z P Li; H Z Lin; S Q Yang
Journal:  Gut       Date:  2005-02       Impact factor: 23.059

Review 3.  Practical management of the increasing burden of non-alcoholic fatty liver disease.

Authors:  Angelina Mouralidarane; Ching-I Lin; Narin Suleyman; Junpei Soeda; Jude A Oben
Journal:  Frontline Gastroenterol       Date:  2010-09-23

Review 4.  Clinical features of nonalcoholic steatohepatitis in Japan: Evidence from the literature.

Authors:  Masafumi Ono; Toshiji Saibara
Journal:  J Gastroenterol       Date:  2006-08       Impact factor: 7.527

5.  High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis.

Authors:  Rohit Kohli; Michelle Kirby; Stavra A Xanthakos; Samir Softic; Ariel E Feldstein; Vijay Saxena; Peter H Tang; Lili Miles; Michael V Miles; William F Balistreri; Stephen C Woods; Randy J Seeley
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

6.  Telmisartan plus propranolol improves liver fibrosis and bile duct proliferation in the PSC-like Abcb4-/- mouse model.

Authors:  Susanne Mende; Sigrid Schulte; Ingo Strack; Heike Hunt; Margarete Odenthal; Galyna Pryymachuck; Maria Quasdorff; Münevver Demir; Dirk Nierhoff; Hans-Peter Dienes; Tobias Goeser; Hans-Michael Steffen; Ulrich Töx
Journal:  Dig Dis Sci       Date:  2012-12-18       Impact factor: 3.199

7.  Selective α1B- and α1D-adrenoceptor antagonists suppress noradrenaline-induced activation, proliferation and ECM secretion of rat hepatic stellate cells in vitro.

Authors:  Ting-ting Liu; Ti-long Ding; Yong Ma; Wei Wei
Journal:  Acta Pharmacol Sin       Date:  2014-10-06       Impact factor: 6.150

8.  Contribution of the sympathetic hormone epinephrine to the sensitizing effect of ethanol on LPS-induced liver damage in mice.

Authors:  Claudia von Montfort; Juliane I Beier; Luping Guo; J Phillip Kaiser; Gavin E Arteel
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-03-06       Impact factor: 4.052

Review 9.  Mouse models in non-alcoholic fatty liver disease and steatohepatitis research.

Authors:  Quentin M Anstee; Robert D Goldin
Journal:  Int J Exp Pathol       Date:  2006-02       Impact factor: 1.925

10.  Sympathetic nervous system catecholamines and neuropeptide Y neurotransmitters are upregulated in human NAFLD and modulate the fibrogenic function of hepatic stellate cells.

Authors:  Barbara Sigala; Chad McKee; Junpei Soeda; Valerio Pazienza; Maelle Morgan; Ching-I Lin; Clare Selden; Sara Vander Borght; Gianluigi Mazzoccoli; Tania Roskams; Manlio Vinciguerra; Jude A Oben
Journal:  PLoS One       Date:  2013-09-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.